Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs

Endocrine Journal

Volumn 57, Issue 10, 2010, Pages 881-893

  Liu, Xuhan ^a   Li, Guosheng ^a   Zhu, Hua ^a   Huang, Lan ^a   Liu, Yali ^a   Ma, Chunmei ^a   Qin, Chuan ^a  

^a INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

Berberine; LXR ; PPAR ; SREBPs; Type 2 diabetes

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE 1; BERBERINE; CARNITINE PALMITOYLTRANSFERASE I; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; FATTY ACID; GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; INSULIN; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; STREPTOZOCIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG STRUCTURE; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; HAMSTER; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIVER WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ANIMALS; BERBERINE; CRICETINAE; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LIVER; MALE; MESOCRICETUS; OBESITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORPHAN NUCLEAR RECEPTORS; PPAR ALPHA; RANDOM ALLOCATION; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEINS;

EID: 78649385842     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-043     Document Type: Article

References (28)

1. de Fourmestraux V, Neubauer H, Poussin C, Farmer P, Falquet L, Burcelin R, Delorenzi M, Thorens B (2004) Transcript profiling suggests that differential metabolic adaptation of mice to a high fat diet is associated with changes in liver to muscle lipid fluxes. J Biol Chem 279: 50743-50753.
2. Jeon JR, Kim JY (2006) Effects of pine needle extract on differentiation of 3T3-L1 preadipocytes and obesity in high-fat diet fed rats. Biol Pharm Bull 29: 2111-2115.
3. Unger RH, Orci L (2000) Lipotoxic diseases of nonadipose tissues in obesity. Int J Obes Relat Metab Disord 24 (Suppl 4): S28-S32.
4. McGarry JD (2002) Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51: 7-18.
5. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL (2000) Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6: 77-86.
6. Jia W, Gao WY, Xiao PG (2003) Antidiabetic drugs of plant origin used in China: compositions, pharmacology, and hypoglycemic mechanisms. Zhongguo Zhong Yao Za Zhi 28: 108-113.
7. Letasiová S, Jantová S, Múcková M, Theiszová M (2005) Antiproliferative activity of berberine in vitro and in vivo. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149: 461-463.
8. Chen QM, Xie MZ (1986) Studies on the hypoglycemic effect of Coptis chinensis and berberine. Yao Xue Xue Bao 21: 401-406.
9. Leng SH, Lu FE, Xu LJ (2004) Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 25: 496-502.
10. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB (2006) Berberine, a natural plant product, activates AMPactivated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 2256-2264.
11. Cheng Z, Pang T, Gu M, Gao AH, Xie CM, Li JY, Nan FJ, Li J (2006) Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta 1760: 1682-1689.
12. Luo J, Quan J, Tsai J, Hobensack CK, Sullivan C, Hector R, Reaven GM (1998) Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 47: 663-668.
13. Danda RS, Habiba NM, Rincon-Choles H, Bhandari BK, Barnes JL, Abboud HE, Pergola PE (2005) Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int 68: 2562-2571.
14. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller Thornberry NA, Zhang BB (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55: 1695-1704.
15. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
16. Ni YX (1988) Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie He Za Zh. 8: 711-713, 707.
17. Yin J, Hu R, Chen M, Tang J, Li F, Yang Y, Chen J (2002) Effects of berberine on glucose metabolism in vitro. Metabolism 51: 1439-1443.
18. Seoane J, Trinh K, O'Doherty RM, Gómez-Foix AM, Lange AJ, Newgard CB, Guinovart JJ (1997) Metabolic impact of adenovirus-mediated overexpression of the glucose-6-phosphatase catalytic subunit in hepatocytes. J Biol Chem 272: 26972-26977.
19. Chen G, Liang G, Ou J, Goldstein JL, Brown MS (2004) Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 101: 11245-11250.
20. Kase ET, Wensaas AJ, Aas V, Højlund K, Levin K, Thoresen GH, Beck-Nielsen H, Rustan AC, Gaster M (2005) Skeletal muscle lipid accumulation in type 2 diabetes may involve the liver X receptor pathway. Diabetes 54: 1108-1115.
21. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, Amemiya-Kudo M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Nagai R, Ishibashi S, Yamada N (2002) Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277: 19353-19357.
22. Ide T, Shimano H, Yahagi N, Matsuzaka T, Nakakuki M, Yamamoto T, Nakagawa Y, Takahashi A, Suzuki H, Sone H, Toyoshima H, Fukamizu A, Yamada N (2004) SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol 6: 351-357.
23. Reddy JK, Hashimoto T (2001) Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 21: 193-230.
24. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, De Minicis S, Nobili L, Salzano R, Omenetti A, Pacetti D, Sigmund S, Benedetti A, Casini A (2006) A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 169: 846-860.
25. Wan YJ, Morimoto M, Thurman RG, Bojes HK, French SW (1995) Expression of the peroxisome proliferator- activated receptor gene is decreased in experimental alcoholic liver disease. Life Sci 56: 307-317.
26. Ip E, Farrell G, Hall P, Robertson G, Leclercq I (2004) Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39: 1286-1296.
27. Yeon JE, Choi KM, Baik SH, Kim KO, Lim HJ, Park KH, Kim JY, Park JJ, Kim JS, Bak YT, Byun KS, Lee CH (2004) Reduced expression of peroxisome proliferator- activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 19: 799-804.
28. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD, Kim JB (2009) Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab 296: E812-E819.